TBGNF Stock - Oxurion N.V.
Unlock GoAI Insights for TBGNF
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $3,000 | $263,000 | $595,000 | $1.13M | $2.08M |
| Gross Profit | $-40,000 | $104,000 | $-271,000 | $-161,000 | $419,000 |
| Gross Margin | -1333.3% | 39.5% | -45.5% | -14.3% | 20.2% |
| Operating Income | $382,000 | $-12,110,000 | $-22,779,000 | $-28,688,000 | $-29,755,000 |
| Net Income | $119,000 | $-18,969,000 | $-31,685,000 | $-29,158,000 | $-28,012,000 |
| Net Margin | 3966.7% | -7212.5% | -5325.2% | -2584.9% | -1348.0% |
| EPS | $0.09 | $-114.80 | $-3726.80 | $-7591.10 | $-7315.40 |
Oxurion NV, a biopharmaceutical company, develops and commercializes medicines for the treatment of eye diseases in Belgium and internationally. Its lead product is JETREA for the treatment of vitreomacular adhesion/vitreomacular traction. The company also develops THR-149, a plasma kallikrein inhibitor, which is in Phase II clinical trials for the treatment of diabetic macular edema (DME); and THR-687, an integrin antagonist which is in Phase II clinical trials for the treatment of DME. It has collaboration agreements with Bicycle Therapeutics, INC Research, and Galapagos NV. The company was formerly known as ThromboGenics NV and changed its name to Oxurion NV in September 2018. Oxurion NV was founded in 1991 and is headquartered in Leuven, Belgium.
Visit WebsiteEarnings History & Surprises
TBGNFEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q3 2021 | Sep 9, 2021 | $-0.36 | — | — | — |
Q1 2021 | Mar 17, 2021 | — | — | — | — |
Q4 2020 | Oct 15, 2020 | — | — | — | — |
Q2 2020 | May 7, 2020 | — | — | — | — |
Q4 2019 | Oct 18, 2019 | — | — | — | — |
Q1 2019 | Mar 7, 2019 | — | — | — | — |
Q4 2018 | Oct 19, 2018 | — | — | — | — |
Q1 2018 | Mar 16, 2018 | — | — | — | — |
Q4 2017 | Oct 20, 2017 | — | — | — | — |
Q2 2017 | Jun 1, 2017 | — | — | — | — |
Q1 2017 | Mar 16, 2017 | — | — | — | — |
Q3 2016 | Aug 25, 2016 | — | — | — | — |
Q2 2016 | May 13, 2016 | — | — | — | — |
Q4 2015 | Nov 30, 2015 | — | — | — | — |
Q3 2015 | Aug 26, 2015 | — | — | — | — |
Q1 2015 | Mar 12, 2015 | — | — | — | — |
Q3 2014 | Aug 28, 2014 | — | — | — | — |
Latest News
Frequently Asked Questions about TBGNF
What is TBGNF's current stock price?
What is the analyst price target for TBGNF?
What sector is Oxurion N.V. in?
What is TBGNF's market cap?
Does TBGNF pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to TBGNF for comparison